Article Details

Wedbush Reaffirms “Outperform” Rating for Entasis Therapeutics (ETTX)

Retrieved on: 2019-04-10 19:03:45

Tags for this article:

Click the tags to see associated articles and topics

Wedbush Reaffirms “Outperform” Rating for Entasis Therapeutics (ETTX). View article details on HISWAI:

Excerpt

<div><b>Sofinnova Ventures</b> Inc bought a new stake in shares of Entasis Therapeutics in the third quarter worth $12,840,000. Luminus Management LLC ...</div>

Article found on:

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up